



Gary P. Oakeson
Registered Patent Attorney
oakeson@tnw.com

March 29, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application No. 10/505,289 filed 07/14/2005

Applicant: Brian Jones et al.

Title: MOBILE PHASE TREATMENT FOR CHROMATOGRAPHY

Group Art Unit: 1723

Attorney Docket No. 25808.US

Sir/Madam:

Transmitted herewith for filing and pursuant to 37 C.F.R. §§ 1.56 and 1.97 is an Information Disclosure Statement. Enclosed also are the following designated documents, as required under 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	Form PTO/SB/08A and PTO/SB/08B list of 22 references submitted for consideration.
	Legible copies of the listed references or their relevant portions.
\boxtimes	Legible copies of the listed <u>non-patent documents and foreign documents</u> or their relevant portions are included.
\boxtimes	Copies of U.S. patents and/or publications are not included pursuant to the Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. 1.98(a)(2)(i).
	All English translations of each non-English reference, if any, within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) (see 37 C.F.R. § 1.98(c)).

GPO/jmw

	The following are included within the Information Disclosure State under 37 C.F.R. § 1.98:	ement if applicable and as
	Concise explanation of relevance of each reference not in I by an English translation.	English and unaccompanied
	Statement that certain listed references not enclosed are sub- enclosed reference.	ostantially cumulative of an
	Statement that certain listed references not enclosed were p submitted to the Office in prior application no. , filed relied upon for an earlier filing date under 35 U.S.C. § 120	on, which is
	n order to secure consideration of the items designated above, one ed, is also enclosed:	or more of the following,
	Statement under 37 C.F.R. § 1.97(e)(1) or (2).	
	Check No, which includes the amount of \$180.00 (constituting the submission fee set forth in 37 C.F.R. § 1.1	- 12 //
Statement n	In the event that 37 C.F.R. § 1.97(c) applies and the Examiner is not meets the requirements of 37 C.F.R. § 1.97(e), or in any other exedit any over payment or charge any additional fees to Deposit Acned.	vent remediable by a fee,
	Respectfully submitted, Gary P. Oakeson Attorney for Applicant Registration No. 44,266	
	THORPE NORTH & WE Customer No. 20,551 P.O. Box 1219 Sandy, Utah 84091-1219 Telephone: (801) 566-663	



IN THE UNITED STATES PATENT & TRADEMARKS OFFICE

1723

EXAMINER:

APPLICANT: Brian Jones et al.

SERIAL NO.: 10/505.289

FILED:

7/14/2005

CONFRM. NO.: 5179

FOR: MOBILE PHASE TREATMENT FOR

CHROMATOGRAPHY

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

DATE OF DEPOSIT: 3-31-06

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO/SB/08A and PTO/SB/08B which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure Statement is filed pursuant to:

M 37 C.F.R. § 1.97 (b)(1) or (3), within three months of the filing date of the application, or before a first office action on the merits, whichever occurs last;

37 C.F.R. § 1.97 (c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1) a statement in accordance with 37 C.F.R. § 1.97(e), or 2) the fee set forth in§1.17(p); or

37 C.F.R. § 1.97 (d), after a Final Office Action or Notice of Allowance, whichever occurs first, but on or before payment of the issue fee, and is accompanied by both 1) a statement in accordance with 37 C.F.R. § 1.97(e), and 2) the fee set forth in§1.17(p).

While no representation is made that any of these references may be "prior art" within the meaning of that term in accordance with 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously submitted or listed, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingly withheld.

A legible copy of each listed U.S. Patent or publication (or relevant portion thereof
which was not previously submitted to, or cited by, the Patent Office is enclosed pursuant to 37
C.F.R. §§ 1.97 and 1.98.
A legible copy of each of the listed non-patent literature and foreign documents of
their relevant portions is enclosed.
Copies of cited U.S. patents and/or publications are NOT enclosed pursuant to the
Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. § 1.98(a)(2)(i).
Copies of the references listed in the accompanying Form PTO/SB/08A AND
PTO/SB/O8B are NOT enclosed because, under 37 C.F.R. § 1.98(d), they were previously cited by
or submitted to the Office in application number , which is relied upon for an
earlier filing date under 35 U.S.C. § 120.
For all listed references that are not either in the English language, or accompanied by a
translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3) is
enclosed attached to each.
The Commissioner is hereby authorized to charge any additional fees associated with this
communication or to credit any overpayment to Deposit Account No. 20-0100.
Dated this 3 day of March, 2006.
Respectfully submitted,
Respectfully submitted,

Gary V. Oakeson Attorney for Applicant Registration No. 44,266

THORPE NORTH & WESTERN, LLP Customer No. 20,551 P.O. Box 1219 Sandy, Utah 84091-1219 Telephone: (801) 566-6633

GPO/jmw Enclosure

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
of 1

Sheet

I	Complete if Known							
ľ	Application Number	10/505,289						
I	Filing Date	7/14/2005						
	First Named Inventor	Brian Jones						
	Art Unit	1723						
ſ	Examiner Name		_					
Ť	Attorney Docket Number	25808.US						

			U.S. PATENT DO	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant
Initials*	No.1	Number-Kind Code ^{2 (ifknown)}	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear
		US-4,404,845	09-20-1983	Schrenker	
		US-5,238,557	08-24-1993	Schneider, et al.	
		US-6,103,112	08-15-2000	Sutton et al.	
		US-4,484,061	11-20-1984	Zelinka et al.	
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.'	Country Code ³ - Number ⁴ - Kind Code ⁵ (I ¹ known)	Date MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	T ⁶	
						_	
						├	
						İ	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

APR 0 3 2006 work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution Substitution Complete if Known for form 1449/PTO Application Number 10/505,289 07/14/2005 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor **Brian Jones** (Use as many sheets as necessary) Art Unit 1723 **Examiner Name** Sheet of 2 Attorney Docket Number 25808.US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		ANDERSEN, THOMAS ET AL., "Separation of polyethylene glycol oligomers using inverse temperature programming in packed capillary liquid chromatography" J. Chromatogr. A. (2001) Vol. 918, pp. 221-226.	
		BRUHEIM, INGE ET AL., "Temperature-Programmed packed Capillary Liquid Chromatography Coupled to Fourier-Transform Infrared Spectroscopy," J. High. Resolut. Chromatogr. (2000) Vol. 23(9), pp. 525-530.	
		DJORDJEVIC, N.M. ET AL., "High Temperature and Temperature Programming in High-Performance Liquid Chromatography: Instrumental Considerations," J. Microcol. Sep. (1999) Vol 11(6), pp. 403-413.	
		FIELDS S.M. ET AL., "Superheated water as eluent in high-temperature high-performance liquid chromatographic separations of steroids on a polymer-coated zirconia column" J. Chromatogr. A. (2001) Vol. 913, pp. 197-204.	
		MCCALLEY, D.V., "Effect of temperature and flow-rate on analysis of basic compounds in high-performance liquid chromatography using a reversed-phase column," J. Chromatogr. A. (2000) Vol. 902, pp. 311-321.	
. 9		MCCOWN, S.M. ET AL., "Solvent Properties and Their Effects on Gradient Elution High- Performance Liquid Chromatography," J. Chromatogr. (1986), Vol. 352, pp. 483-492.	
		MOLANDER, P. ET AL., "Determination of 1-(2-methoxyphenyl)piperazine derivatives of isocyanates at low concentrations by temperature-programmed miniaturized liquid chromatography," J. Chromatogr. A. (2000) Vol 892, pp. 67-74.	
		MOLANDER, P. ET AL., "Determination of low levels of an antioxidant in polyolefins by large-volume injection temperature-programmed packed capillary liquid chromatography", J. Chromatogr. A. (1999) Vol. 864, pp. 103-109.	
		MOLANDER, P. ET AL., "Temperature Effects on Packed-Capillary Liquid Chromatography of the X-ray Contrast Agent Iodixanol," J. Chromatogr. Sci. (2000) Vol. 38, pp. 157-161.	
	1	<u></u>	

Examiner	Date	
Signature	Considered	

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known			
Substitute for form 1449/PTO			9/PTO	Application Number	10/505,289		
			ON DISCLOSURE	Filing Date	07/14/2005		
STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Brian Jones				
(Use as many sneets as necessary)				Art Unit	1723		
				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	25808.US		

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,	
Initials*	No.1	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MOLANDER, PAAL ET AL., "Separation of Ceramides by Sub-Ambient Temperature-Assisted large volume Injection in Temperature-Programmed Packed Capillary Liquid Chromatography," J. High. Resolut. Chromatogr. (2000) Vol. 23 (11) pp. 653-655.	
		MOLANDER, PAAL ET AL., "Simultaneous dual-mechanism separation of a semicrystalline polymer blend on large-pore silica by temperature-programmed packed capillary liquid chromatography" J. Sep. Sci. (2001) Vol. 24, pp. 136-140.	
		MOLANDER, PAAL ET AL., "Temperature-Programmed Packed Capillary Liquid Chromatography Separation with Large Volume On-Column Focusing of Retinyl Esters," J. High Resolut. Chromatogr. (1999) Vol. 9, pp. 490-494.	
		NORDSTROM, O. ET AL., "Evaluation of Temperature Programming for Gradient Elution in Packed Capillary Liquid Chromatography Coupled to Electrochemical Detection," J. Microcol Sept. (2001) pp. 179-185.	
		POPPE, H. AND J. C. KRAAK, "Influence of Thermal Conditions on the Efficiency of High- Performance Liquid Chromatographic Columns," J. Chromatogr. (1983) Vol. 282, pp. 399-412.	
		TRONES, ROGER ET AL., "Hindered amine stabilizers investigated by the use of packed capillary temperature programmed liquid chromatography II: Poly-(N-β-hydroxyethyl-2,2,6,6-tetramethyl-4-hydroxypiperidyl succinate)", J. Chromatogr. A. (2000) Vol. 902, pp. 421-426.	
		TRONES, ROGERT ET AL., "Hindered amine stabilizers investigated by the use of packed capillary temperature-programmed liquid chromatography I. Poly ((6-1,1,3,3-tetramethylbutyl)-amino)-1,3,5-triazine-2,4-diyl)(2,2,6,6-tetramethyl-4-piperidyl)imino)-1,6-hexaneiyl ((2,2,6,6-tetramethyl-4-piperidyl)imino))," J. Chromatogr. A. (2000) Vol. 874, pp. 65-71.	
		WOLCOTT, R.G. ET AL., "Control of column temperature in reversed-phase liquid chromatography," J. Chromatogr. A. (2000) Vol. 869, pp. 211-230.	
		YAN, BINGWEN ET AL., "High-Temperature Ultrafast Liquid Chromatography," Anal. Chem., 2000, Vol. 72, pp. 1253-1262.	

Examiner	Date	
Signature	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.